MetLife Investment Management’s Ovid Therapeutics OVID Stock Holding History

MetLife Investment Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244K	Buy	+90,587	New	+$234K	﹤0.01%	2316
2024 Q2	–	Sell	-16,796	Closed	-$46.7K	–	2912
2024 Q1	$51.2K	Sell	16,796 -14,921	-47%	-$49.9K	﹤0.01%	2713
2023 Q4	$102K	Hold	31,717	–	–	﹤0.01%	2598
2023 Q3	$122K	Hold	31,717	–	–	﹤0.01%	2478
2023 Q2	$104K	Buy	+31,717	New	+$108K	﹤0.01%	2655
2020 Q4	–	Sell	-20,939	Closed	-$120K	–	2299
2020 Q3	$120K	Hold	20,939	–	–	﹤0.01%	2129
2020 Q2	$154K	Buy	+20,939	New	+$97.9K	﹤0.01%	2047

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

MetLife Investment Management's OVID Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 90,587 shares worth $244K. The stake represents ﹤0.01% of the portfolio and ranks #2316 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in OVID as recently as Q1 2024.

MetLife Investment Management first reported a position in OVID in Q2 2020 and has held it in 7 quarters since. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

MetLife Investment Management held 90,587 shares of Ovid Therapeutics worth $244K as of Q2 2026.
Ovid Therapeutics was a new MetLife Investment Management position in Q2 2026.
Ovid Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2316 holding.
MetLife Investment Management first reported a position in Ovid Therapeutics in Q2 2020 and has held it in 7 quarters since.
130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.